Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

Monopar Therapeutics Inc.’s MNPR share price has dipped by 9.91%, which has investors questioning if this is right time to ...

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris ...

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced ...

A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced ...

The treatment combines brentuximab vedotin with doxorubicin, dacarbazine and vinblastine, which is given to patients as an ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025AVA6103 IND-enabling studies underway with a Phase 1 trial ...

Southside Cancer Care Centre in Miranda initiated as first site for Race’s Phase I trial of cardioprotective therapy RC220 in ...

Chemotherapy plus local therapy improved overall survival and disease-free survival when compared to local therapy alone.